News

Utilization of ambulatory care services declined during the COVID-19 pandemic, especially among socioeconomically disadvantaged Americans.

These behind-the-scenes, essential personnel remain a significant part of health care and is a field with growth opportunities, but remain a field in need of public awareness to enable its stability.

New models suggest that climate change will force animal populations to migrate, creating conditions for new viruses to emerge and jump to humans.

A Colorado person tested positive for avian influenza. The patient worked closely with poultry, their only symptom was fatigue, and they have since recovered after a few days.

Cancer increased risk of COVID-19 among the vaccinated, with subsequent "significant and substantial" hospitalizations and mortality.

Antibiotic overuse is a longstanding problem in the medical community. A new study highlights the benefits of accurate point-of-care testing to differentiate between bacteria and viruses.

Today, the FDA approved oteseconazole to treat recurrent vulvovaginal candidiasis (RVVC). Marketed under the name Vivjoa, the drug is the first FDA approval for manufacturer Mycovia Pharmaceuticals.

Ensovibep, the COVID-19 antiviral treatment developed by Novartis and Molecular Partners, is facing delays in its quest for emergency authorization after the FDA indicated more study data is required.

If authorized, this would be the first vaccine applicable to the youngest pediatric group.

These paramount medical personnel behind the scenes are facing staffing challenges that could be bordering on a national crisis in public health.

Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.

The filing included data from their phase 2/3 trial in this pediatric age group.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

Immune escape for the BA.2 subvariant, or “stealth Omicron,” was not as severe as that of the original Omicron variant, a new study suggests.

The supplemental new drug application is expanded to include the youngest COVID-19 patients.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.

The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.

Investigators used electronic health records (EHR) to perform surveillance of the safety of 3 doses of the COVID-19 mRNA vaccines.

The pandemic offered valuable lessons on improving the translation of evidence to practice, according to a recent survey of academic medical centers.

Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.

Although the development of antibiotics remains a challenge, there are some legislative strategies that could make it more attractive and get more players involved.

A group of over 60 scientists participated in a communication to the federal agency to advocate for measuring these cells in COVID-19 vaccine trials.

The World Health Organization (WHO) has strongly recommended nirmatrelvir and ritonavir (Paxlovid), as well as remdesivir, for COVID-19 treatment. WHO emphasized that these medicines should be made accessible to low- and middle-income countries.

Investigators consider the low rate of vaccination in the rapidly increasing migrant populations in Europe, and call for improved strategies.

The tactic is seen as a way to ensure supplies of novel drugs in face of resistance crisis.